Elizabeth (Liz) McKee Anderson has served on our Board of Directors since March 2015.
Ms. Anderson brings more than 30 years of leadership in biotechnology, pharmaceuticals, and vaccines, spending her career bringing innovative medicines to market to prevent or treat life-threatening diseases.
Ms. Anderson has served on the board of directors of GSK Plc (NYSE: GSK), a pharmaceutical company, since September 2022. Ms. Anderson has served on the board of directors of BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a biotechnology company, since July 2019. Since November 2018, Ms. Anderson has served on the board of directors of Insmed Incorporated (Nasdaq: INSM), a biopharmaceutical company. Ms. Anderson previously served in various roles at Janssen Pharmaceuticals, Inc., a Johnson & Johnson company focusing on pharmaceuticals, from 2003 to 2014, most recently as Worldwide Vice President, Commercial Leader, Infectious Diseases and Vaccines, from 2012 to 2014 and Worldwide Vice President, Global Strategic Marketing and Market Access, Vaccines from 2010 to 2012. Prior to that, Ms. Anderson served as Vice President and General Manager for Wyeth Lederle Vaccines, a division of Wyeth, a pharmaceutical company.
Ms. Anderson received a B.Eng. in Engineering and Technical Management from Rutgers, The State University of New Jersey-New Brunswick and an MBA in Finance from Loyola University Maryland.
What is Elizabeth M. Anderson's net worth?
The estimated net worth of Elizabeth M. Anderson is at least $865.99 thousand as of September 22nd, 2026. Ms. Anderson owns 4,333 shares of Revolution Medicines stock worth more than $865,993 as of September 25th. This net worth evaluation does not reflect any other investments that Ms. Anderson may own. Learn More about Elizabeth M. Anderson's net worth.
How do I contact Elizabeth M. Anderson?
Has Elizabeth M. Anderson been buying or selling shares of Revolution Medicines?
During the last ninety days, Elizabeth M. Anderson has sold $1,958,004.72 of Revolution Medicines stock. Most recently, Elizabeth M. Anderson sold 10,143 shares of the business's stock in a transaction on Tuesday, September 22nd. The shares were sold at an average price of $193.04, for a transaction totalling $1,958,004.72. Following the completion of the sale, the director now directly owns 4,333 shares of the company's stock, valued at $836,442.32. Learn More on Elizabeth M. Anderson's trading history.
Who are Revolution Medicines' active insiders?
Revolution Medicines' insider roster includes Jack Anders (Insider), Elizabeth Anderson (Director), Jeff Cislini (General Counsel), Mark Goldsmith (Insider), Margaret Horn (COO), Stephen Kelsey (President, Research & Development), Lorence Kim (Director), Vincent Miller (Director), Sushil Patel (Director), Alan Sandler (Chief Development Officer), Thilo Schroeder (Director), Peter Svennilson (Director), Xiaolin Wang (Insider), Barbara Weber (Director), and Lin Wei (Chief Medical Officer). Learn More on Revolution Medicines' active insiders.
Are insiders buying or selling shares of Revolution Medicines?
In the last twelve months, insiders at the sold shares 37 times. They sold a total of 870,563 shares worth more than $125,088,721.92. The most recent insider tranaction occured on September, 22nd when Director
Elizabeth M. Anderson sold 10,143 shares worth more than $1,958,004.72. Insiders at Revolution Medicines own 7.6% of the company.
Learn More about insider trades at Revolution Medicines. Information on this page was last updated on 9/22/2026.
